Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 3/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 2/20 | 0.40 |
| ▸ | TACR1 | P25103 | 2/20 | 0.38 |
| ▸ | MC4R | P32245 | 2/20 | 0.38 |
| ▸ | MC5R | P33032 | 2/20 | 0.38 |
| ▸ | MC3R | P41968 | 2/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6318655 | 0.88 | GHSR (0.44) | GHSROPRM1MMP9MMP8F2 | |
| SCHEMBL6319005 | 0.86 | F2 (0.46) | GHSROPRM1MMP9MMP8F2 | |
| SCHEMBL6318999 | 0.86 | F2 (0.46) | GHSROPRM1MMP9MMP8F2 | |
| SCHEMBL6318044 | 0.84 | GHSR (0.63) | GHSROPRM1F2 | |
| SCHEMBL6318920 | 0.84 | GHSR (0.63) | GHSROPRM1F2 | |
| SCHEMBL8905496 | 0.82 | GHSR (0.60) | GHSROPRM1F2 | |
| SCHEMBL8905486 | 0.82 | GHSR (0.60) | GHSROPRM1F2 | |
| SCHEMBL7065014 | 0.81 | ALDH1A1 (0.45) | OPRM1 | |
| SCHEMBL27488811 | 0.81 | ALDH1A1 (0.45) | OPRM1 | |
| SCHEMBL7065323 | 0.81 | MMP9 (0.51) | GHSRMMP9MMP8TACR1MC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030055261-A1 | Compounds with growth hormone releasing properties | HELSINN THERAPEUTICS (U.S.), INC. | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055261-A1 | Compounds with growth hormone releasing properties | GHRHR, GHSR, IGFBP1 | GHSR 2/4885OPRM1 792/4885MMP9 2831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.